Overweight Or Obesity / SYH2069 Injection / SYH2069 Injection Placebo · Phase 2 Trial

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

ClinicalTrials.gov · September 4, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned Phase 2 randomized controlled trial of SYH2069 injection versus placebo in non-diabetic obese participants, with a primary endpoint of relative percentage change in body weight at 28 weeks. No results are posted in this registry record; the study has not yet begun recruitment.

What was studied

Phase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Overweight or Obesity; age from 18 Years; to 65 Years. Intervention: Treatment group B; Treatment group C; Treatment group D; Treatment group E; Treatment group F; Treatment group G; Treatment group H. Compared with: Treatment group A — Active Comparator; Treatment group I — Placebo Comparator. n = 360. 1 site: China.

Key findings

Safety

No effect size, safety data, or statistical power information available.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a clinical trial registry record with no posted results; it describes a planned Phase 2 interventional study in obesity without diabetes, currently not yet recruiting.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Relative percentage change in body weight from baseline at of treatment at 28 weeks of treatment (assessed at 28 weeks)

DesignPhase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose

PopulationOverweight or Obesity; age from 18 Years; to 65 Years

Sample size360

InterventionTreatment group B; Treatment group C; Treatment group D; Treatment group E; Treatment group F; Treatment group G; Treatment group H

ComparatorTreatment group A — Active Comparator; Treatment group I — Placebo Comparator

Setting1 site: China

Reported figures

Quoted from the source exactly as published.

Planned enrollment360

PhasePhase 2

Primary outcome measureRelative percentage change in body weight from baseline at 28 weeks of treatment

Study duration28 weeks

Caveats

This is a registry record only; no results are posted or available.
Study recruitment has not yet begun (NOT_YET_RECRUITING status).
No baseline characteristics, inclusion/exclusion criteria detail, or dosing regimen provided in registry text.
No effect size, safety data, or statistical power information available.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2 randomized controlled trial planned; design details sparse in registry.

Directness

moderate

Primary outcome is body weight change, a clinically relevant measure in obesity.

Consistency

insufficient

No results reported; consistency cannot be assessed.

Risk of bias

insufficient

Placebo-controlled design suggested; detail on blinding and conduct not in registry.

Sample adequacy

moderate

Estimated enrollment 360 participants; no power calculation or justification stated.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07803991). This is a study registration, not published results. Lead sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 360 participants (ESTIMATED). Conditions: Overweight or Obesity. Interventions: DRUG: SYH2069 Injection; DRUG: SYH2069 Injection Placebo. Primary outcome measures: Relative percentage change in body weight from baseline at of treatment at 28 weeks of treatment , 28 weeks. Brief summary: To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT07803991Overweight Or ObesitySYH2069 InjectionSYH2069 Injection PlaceboCSPC Ouyi Pharmaceutical Co.